H.C. Wainwright assumed coverage of Cogent Biosciences with a Buy rating and $28 price target. The company is addressing both rare and common tumor types with a next-generation precision oncology pipeline, the analyst tells investors in a research note. The firm says Cogent us improving upon the safety profile of KIT inhibitors with bezuclastinib.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on COGT:
- Cogent Biosciences treatment of mastocytosis granted orphan status
- Cogent Biosciences price target lowered to $23 from $24 at Needham
- Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
- Cogent Biosciences reports Q4 EPS (56c), consensus (52c)
- Needham biotech analysts to hold an analyst/industry conference call
